Published in:
Open Access
01-12-2010 | Poster presentation
Switch to once or twice daily unboosted atazanavir in a cohort of stable HIV patients: strong differences in drug exposure and virological outcome
Authors:
T Baudry, A Boibieux, MC Gagnieu, L Cotte, JM Livrozet, P Miahles, D Makhloufi, C Chidiac, D Peyramond, T Ferry
Published in:
Journal of the International AIDS Society
|
Special Issue 4/2010
Login to get access
Excerpt
Switch to once daily unboosted (u) atazanavir (ATV) is an attractive option for HIV-infected patients with undetectable viral load, due to its convenience and favorable metabolic profile. However, due to a large interindividual variability, increased risk of inadequate ATV plasma concentrations (ATVc) and virological failure (VF) may be observed. Dividing the daily dose in a twice a day (BID) regimen could increase ATVc and improve virological success. …